A comparison between on-demand usage of rFVIIa vs prophylaxis use of emicizumab in high titer inhibitory hemophilia A patients in Iran: A cost–utility analysis

BACKGROUND: Hemophilia A (HA) is an inherited X-linked bleeding disease with costly treatment, especially for high titer inhibitory patients. Emicizumab, a new humanized bispecific antibody, has been approved for use to prevent or reduce the frequency of bleeding episodes in HA patients with inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Saiyarsarai, Parisa, Robabpour Derakhshan, Atefeh, Khedmati, Jamaleddin, Eshghi, Peyman, Seyedifar, Meysam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
4200
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500655/
https://www.ncbi.nlm.nih.gov/pubmed/34622828
http://dx.doi.org/10.1097/MD.0000000000027303

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500655/
https://www.ncbi.nlm.nih.gov/pubmed/34622828
http://dx.doi.org/10.1097/MD.0000000000027303

Ejemplares similares